Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Chemomab Therapeutics Ltd. (CMMB) M&A Call Prepared Remarks Transcript
Seeking Alpha7/8/2026Neutral
CMMB
Chemomab Therapeutics Ltd DRCNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$10.48M
P/E Ratio
—
EPS
$-1.12
Beta
0.64
52W High
$4.50
52W Low
$1.35
50-Day MA
$1.71
200-Day MA
$1.97
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
12.94
PEG Ratio
—
About Chemomab Therapeutics Ltd DRC
Chemomab Therapeutics Ltd. is dedicated to the research and development of biological drugs for the treatment of inflammatory and fibrotic diseases. The company is headquartered in Tel Aviv, Israel.
Fundamentals
| Revenue (TTM) | 0 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-7.86M |
| Operating Margin | 0.00% |
| Return on Equity | -70.60% |
| Return on Assets | -40.30% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $1.49 |
| Price-to-Book | 0.99 |
| Price-to-Sales (TTM) | — |
| EV/Revenue | - |
| EV/EBITDA | 0.33 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 0.00% |
| Shares Outstanding | $7.33M |
| Float | $6.40M |
| % Insiders | 11.09% |
| % Institutions | 7.86% |
Historical Volatility
HV 10-Day
41.57%
HV 20-Day
181.40%
HV 30-Day
150.56%
HV 60-Day
121.14%
HV Rank
94.4%
Volatility is currently contracting
Analyst Ratings
Consensus ($5.00 target)
1
Strong Buy1
BuyLatest News
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis
Chemomab and Scipher announced a merger agreement to advance nebokitug into a Phase 2 precision medicine trial for the treatment of rheumatoid arthritis.
GlobeNewsWire7/8/2026Neutral
Chemomab Therapeutics Announces First Quarter 2026 Financial Results and Provides Corporate Update
—New C linical and Translational Data Presented at Major Medical Meetings Further Confirms the Disease-Modifying Potential of Nebokitug in Primary Sclerosing Cholangitis and Suggests Possible Additional Benefit in PSC Patients with Co-Existing IBD— —Company Continues to Advance Multiple Partnering Options for Nebokitug— TEL AVIV, Israel, May 14, 2026 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical-stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced financial and operating results for the first quarter ended March 31, 2026, and provided a corporate update.
GlobeNewsWire5/14/2026Neutral
Turn research into an automated options-selling system
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on CMMB and any ticker you trade — then tracks every position and per-strategy win rate.
More HEALTHCARE Stocks
Data last updated: 7/29/2026